Business, energy, technology, markets and global industry news from Business News Today

Japan

PharmaDeviceNews Japan
Representative image: Oral preventive therapy for hereditary angioedema as BioCryst Pharmaceuticals expands ORLADEYO into younger children in Japan, strengthening the drug’s global pediatric HAE growth opportunity.
Pharma & Biotech

Japan approves pediatric ORLADEYO as BioCryst Pharmaceuticals expands hereditary angioedema reach

Japan expands ORLADEYO to children aged 2 to under 12 as BioCryst Pharmaceuticals builds its global HAE franchise. See what comes next.

Read More
Representative image: Japan’s approval of IMCIVREE for acquired hypothalamic obesity expands Rhythm Pharmaceuticals’ global rare-disease footprint, strengthening the company’s growth story as setmelanotide reaches another major pharmaceutical market.
Pharma & Biotech

Japan clears IMCIVREE for acquired hypothalamic obesity as Rhythm Pharmaceuticals expands global reach

Japan approves IMCIVREE for acquired hypothalamic obesity, expanding Rhythm Pharmaceuticals’ global franchise. See what the approval means for growth.

Read More
Galderma expands Alastin professional skincare across Japan and key Asia Pacific medical aesthetics markets as demand for procedure-linked skincare grows. Representative image.
Pharma & Biotech

Galderma is taking Alastin deeper into Asia, but this launch is about more than skincare

Galderma expands Alastin across Japan and Asia Pacific, linking premium skincare with rising demand for aesthetic procedures.

Read More
Representative image of a cancer infusion clinic, reflecting Sanofi’s Sarclisa subcutaneous approval in Japan and the shift toward less burdensome multiple myeloma treatment delivery.
Pharma & Biotech

Could Sanofi’s Sarclisa SC approval change how Japan treats multiple myeloma?

Find out how Sanofi’s Sarclisa SC approval in Japan could change multiple myeloma treatment delivery and strengthen its oncology strategy today!

Read More
Pharma & Biotech

Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut

Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.

Read More
Pharma & Biotech

Ustekinumab biosimilar approved in Japan: Can Samsung Bioepis expand its global autoimmune footprint?

Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.

Read More
Pharma & Biotech

Is givinostat’s entry into Japan a turning point for DMD care and for JCR Pharmaceuticals’ rare disease strategy?

Find out how Italfarmaco and JCR are bringing the DMD drug givinostat to Japan and what it means for rare disease innovation in Asia.

Read More